Enantiomer of azopodophyllotoxin derivative su056
AssigneeOregon Health & Science University
InventorsSanjay Malhotra, Dhanir Tailor, Arpit Dheeraj
Life of this patent
Estimating the term…
Abstract
The present invention concerns a novel enantiomer of 9-(3-fluorophenyl)-5-(2-hydroxyethyl)-6,9-dihydro-[1,3]dioxolo[4,5-g]furo[3,4-b]quinolin-8 (5H)-one (SU056), as well as pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising it, and its uses in medical treatments, particularly including cancer treatments.
Claims15
A composition comprising(S)-9-(3-fluorophenyl)-5-(2-hydroxyethyl)-6,9-dihydro-[1,3]dioxolo[4,5-g]furo[3,4-b]quinolin-8(5H)-one, or a pharmaceutically acceptable salt, co-crystal, ester, solvate, hydrate, isomer (including optical isomers, racemates, or other mixtures thereof), tautomer, isotope, polymorph, or pharmaceutically acceptable prodrug thereof, in an enantiomeric excess of (R)-9-(3-fluorophenyl)-5-(2-hydroxyethyl)-6,9-dihydro-[1,3]dioxolo[4,5-g]furo[3,4-b]quinolin-8(5H)-one, or a pharmaceutically acceptable salt, co-crystal, ester, solvate, hydrate, isomer (including optical isomers, racemates, or other mixtures thereof), tautomer, isotope, polymorph, or pharmaceutically acceptable prodrug thereof.
3-15. (canceled)
The method of claim 7, wherein the cancer expressing YB1 protein is selected from the group consisting of ovarian cancer, endometrial cancer, fallopian tube cancer, and cervical cancer, breast cancer, lung cancers, prostate cancer, colorectal cancer, bladder cancer, melanoma, liver cancer, multiple myeloma, soft tissue sarcoma, osteosarcoma, Ewing's sarcoma, glioblastoma, acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, lymphoma, kidney cancer, renal cell carcinoma, osteosarcoma, pancreatic cancer, head and neck cancer, nasopharyngeal carcinoma, and gastric cancer.
The method of claim 8, wherein the cancer expressing YB1 (YBX1) protein in a subject is an ovarian cancer, the method further comprising administering to the subject in need thereof a pharmaceutically effective amount of a taxane compound, or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.